Anti-IRF3 antibody [EP2419Y]
- BOND RX™ Validated
- 20ul selling size
- RabMAb
- Recombinant
- KO Validated
- What is this?
1
(1 Review)
|
(30 Publications)
Rabbit Recombinant Monoclonal IRF3 antibody. Suitable for IHC-P, IP, WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 30 publications.
View Alternative Names
Interferon regulatory factor 3, IRF-3, IRF3
- Flow Cyt (Intra)
Lab
Flow Cytometry (Intracellular) - Anti-IRF3 antibody [EP2419Y] (AB76409)
Intracellular Flow Cytometry analysis of HeLa (Human cervix adenocarcinoma epithelial cell) cells labeling IRF3 with Purified 76409 at 1/20 dilution (10 μg/ml) (Red). Cells were fixed with 4% Paraformaldehyde and permeabilised with 90% Methanol. A Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) secondary antibody was used at 1/2000. Isotype control - Rabbit monoclonal IgG (Black). Unlabeled control - Cell without incubation with primary antibody and secondary antibody (Blue).
- IHC-P
Lab
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IRF3 antibody [EP2419Y] (AB76409)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human bladder carcinoma tissue sections labeling IRF3 with Purified 76409 at 1 : 100 dilution (1.55 µg/ml). Heat mediated antigen retrieval using Bond™ Epitope Retrieval Solution 2 (pH 9.0) . Rabbit specific IHC polymer detection kit HRP/DAB (ab209101) was used as the secondary antibody. Negative control : PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
- IP
Lab
Immunoprecipitation - Anti-IRF3 antibody [EP2419Y] (AB76409)
Purified ab76409 at 1/20 dilution (0.8μg) immunoprecipitating IRF3 in HeLa whole cell lysate.
Lane 1 (input) : HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate 10μg
Lane 2 (+) : ab76409 + HeLa whole cell lysate.
Lane 3 (-) : Rabbit monoclonal IgG (ab172730) instead of ab76409 in HeLa whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/1000 dilution) was used for Western blotting.
Blocking Buffer and concentration : 5% NFDM/TBST.
Diluting buffer and concentration : 5% NFDM/TBST.
Observed band size : 47 kDa
Fresh lysate need to be used to avoid protein degradation.
All lanes:
Immunoprecipitation - Anti-IRF3 antibody [EP2419Y] (ab76409)
Predicted band size: 47 kDa
false
- WB
Unknown
Western blot - Anti-IRF3 antibody [EP2419Y] (AB76409)
We are unsure how to define the extra bands.
All lanes:
Western blot - Anti-IRF3 antibody [EP2419Y] (ab76409) at 1/1000 dilution
Lane 1:
HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate at 20 µg
Lane 2:
Jurkat (Human T cell leukemia T lymphocyte) whole cell lysate at 20 µg
Lane 3:
U-937 (Human histiocytic lymphoma monocyte) whole cell lysate at 20 µg
Lane 4:
THP-1 (Human monocytic leukemia monocyte) whole cell lysate at 20 µg
Lane 5:
Daudi (Human Burkitt's lymphoma lymphoblast) whole cell lysate at 20 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Predicted band size: 47 kDa
false
- WB
Lab
Western blot - Anti-IRF3 antibody [EP2419Y] (AB76409)
Lanes 1 - 2 : Merged signal (red and green). Green - ab76409 observed at 50 kDa. Red - loading control ab8245 (Mouse anti-GAPDH antibody [6C5]) observed at 37kDa.
ab76409 was shown to react with IRF3 in wild-type A549 cells in western blot with loss of signal observed in IRF3 knockout cell line ab267097 (IRF3 knockout cell lysate ab256953). Wild-type and IRF3 knockout A549 cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% milk in TBS-T (0.1% Tween®) before incubation with ab76409 and ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-IRF3 antibody [EP2419Y] (ab76409) at 1/1000 dilution
Lane 1:
Wild-type A549 cell lysate at 20 µg
Lane 2:
IRF3 knockout A549 cell lysate at 20 µg
Lane 2:
Western blot - Human IRF3 knockout A549 cell line (<a href='/en-us/products/cell-lines/human-irf3-knockout-a549-cell-line-ab267097'>ab267097</a>)
Predicted band size: 47 kDa
Observed band size: 50 kDa
false
- WB
Lab
Western blot - Anti-IRF3 antibody [EP2419Y] (AB76409)
Lanes 1 - 4 : Merged signal (red and green). Green - ab76409 observed at 50 kDa. Red - loading control, ab8245 observed at 37 kDa.
ab76409 was shown to react with IRF3 in wild-type HeLa. Loss of signal was observed when knockout cell line ab255345 (knockout cell lysate ab263784) was used. Wild-type and IRF3 knockout samples were subjected to SDS-PAGE. ab76409 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-IRF3 antibody [EP2419Y] (ab76409) at 1/1000 dilution
Lane 1:
Jurkat cell lysate at 20 µg
Lane 2:
MCF7 cell lysate at 20 µg
Lane 2:
Western blot - Human IRF3 knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-irf3-knockout-hela-cell-line-ab255345'>ab255345</a>)
Lane 3:
Wild-type HeLa cell lysate at 20 µg
Lane 4:
IRF3 knockout HeLa cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/20000 dilution
Predicted band size: 47 kDa
Observed band size: 47 kDa,50 kDa
false
- WB
Unknown
Western blot - Anti-IRF3 antibody [EP2419Y] (AB76409)
Lanes 1 - 4 : Merged signal (red and green). Green - ab76409 observed at 50 kDa. Red - loading control, ab8245, observed at 37kDa.
ab76409 was shown to react with IRF3 in wild-type HAP1 cells alond with additional cross-reactive bands. No band was observed when IRF3 knockout samples were used. Wild-type and IRF3 knockout samples were subjected to SDS-PAGE. ab76409 and ab8245 (loading control to GAPDH) were both diluted 1/1000 and 1/10,000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-IRF3 antibody [EP2419Y] (ab76409) at 1/1000 dilution
Lane 1:
Wild-type HAP1 cell lysate at 20 µg
Lane 2:
IRF3 knockout HAP1 cell lysate at 20 µg
Lane 3:
HeLa cell lysate at 20 µg
Lane 4:
Jurkat cell lysate at 20 µg
Predicted band size: 47 kDa
false
Related conjugates and formulations (1)
-
Anti-IRF3 antibody [EP2419Y] - BSA and Azide free
Reactivity data
Product details
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
IRF3 participates in the regulation of type I interferon (IFN) response a fundamental antiviral defense mechanism. IRF3 when phosphorylated forms a complex with CBP/p300 which then translocates to the nucleus to drive the expression of IFN-stimulated genes. This action strengthens the innate immune response and boosts the body's ability to counteract viral infections. Its activity and regulation are significant for maintaining a balanced immune response without excessive inflammation.
Pathways
IRF3 is involved in the Toll-like receptor (TLR) and RIG-I-like receptor (RLR) signaling pathways both essential in pathogen recognition and response. Within these pathways IRF3 interacts with proteins such as MAVS and TBK1 to propagate immune signaling. The activation of IRF3 in these pathways results in the production of type I interferons and other cytokines orchestrating an effective antiviral response. These interactions highlight the protein's central role in mediating immune signaling cascades.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (30)
Recent publications for all applications. Explore the full list and refine your search
iScience 28:113046 PubMed40717771
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cell communication and signaling : CCS 23:306 PubMed40597187
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cell biology and toxicology 41:82 PubMed40335763
2025
Applications
Unspecified application
Species
Unspecified reactive species
Human molecular genetics 33:1555-1566 PubMed38796715
2024
Applications
Unspecified application
Species
Unspecified reactive species
Nucleic acids research 52:5698-5719 PubMed38587186
2024
Applications
Unspecified application
Species
Unspecified reactive species
Life science alliance 6: PubMed37553253
2023
Applications
Unspecified application
Species
Unspecified reactive species
Cancers 15: PubMed36980689
2023
Applications
Unspecified application
Species
Unspecified reactive species
Viruses 15: PubMed36851534
2023
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in cardiovascular medicine 9:791143 PubMed36082118
2022
Applications
Unspecified application
Species
Unspecified reactive species
Gut microbes 14:2045046 PubMed35258405
2022
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com